Home › Companies › UROGEN PHARMA LTD. › 2024-2025

UROGEN PHARMA LTD. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and UROGEN PHARMA LTD.’s Form 8-K, filed 2024-08-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

12Ballot items
132Asset managers
1,207Fund votes
2024-08-06Meeting date

Proxy season: 2024-2025 2025-2026

Explore UROGEN PHARMA LTD. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by UROGEN PHARMA LTD.

These tallies are UROGEN PHARMA LTD.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-08-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

UROGEN PHARMA LTD. — official shareholder meeting results, meeting held 2024-08-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Arie Belldegrun, M.D., FACS	24,210,538	--	--	2,096,113	6,748,640	Majority: yes
Elect Director: Elizabeth Barrett	26,265,811	--	--	40,840	6,748,640	Majority: yes
Elect Director: Cynthia M. Butitta	25,614,657	--	--	691,994	6,748,640	Majority: yes
Elect Director: Fred E. Cohen, M.D., D.Phil.	25,753,702	--	--	552,949	6,748,640	Majority: yes
Elect Director: Stuart Holden, M.D.	25,594,793	--	--	711,858	6,748,640	Majority: yes
Elect Director: James A. Robinson, Jr.	26,184,412	--	--	122,239	6,748,640	Majority: yes
Elect Director: Leana S. Wen, M.D., M.Sc.	26,092,046	--	--	214,605	6,748,640	Majority: yes
Elect Director: Daniel G. Wildman	26,274,644	--	--	32,007	6,748,640	Majority: yes
Proposal 2 - 2024 Compensation Policy. The shareholders approved the 2024 Compensation Policy.	22,359,904	3,433,075	513,672	--	6,748,640	Majority: yes
Proposal 3 - 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.	22,707,108	3,050,813	548,730	--	6,748,640	Majority: yes
Proposal 4 - Advisory vote on the compensation of the Company's named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy s	22,609,477	3,143,555	553,619	--	6,748,640	Majority: yes
Proposal 5 - Engagement of PricewaterhouseCoopers LLP as independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's 2025 annual meeting of shareholder	33,039,893	8,345	7,053	--	0	Majority: yes

Source: UROGEN PHARMA LTD., Form 8-K, filed with the SEC on 2024-08-08 — read the filing on EDGAR.

How asset managers voted at the UROGEN PHARMA LTD. 2024-2025 meeting

Each item below shows how the 132 asset managers that disclosed a UROGEN PHARMA LTD. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 22,609,477AGAINST: 3,143,555

UROGEN PHARMA LTD.’s own tally for this item (“Proposal 4 - Advisory vote on the compensation of the Company's named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in t”): 22,609,477 for, 3,143,555 against, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 54.9% for, 8% against (63% of the company cast a for/against vote).

The 131 asset managers below cast 89% of the shares they voted on this item FOR (18,882,101 for, 2,412,390 against).

FOR 87%11%

FOR: 18,882,101 (86.7%)AGAINST: 2,412,390 (11.1%)ABSTAIN: 495,606 (2.3%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Against	Abstain	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	4,548,599	0	0	For
RTW INVESTMENTS, LP	3,557,347	0	0	For
RA CAPITAL MANAGEMENT, L.P.	3,082,911	0	0	For
MENORA MIVTACHIM HOLDINGS LTD.	0	2,287,899	0	Against
GREAT POINT PARTNERS LLC	2,045,722	0	0	For
Cormorant Asset Management, LP	1,469,350	0	0	For
BlackRock	827,848	9,639	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	816,853	0	0	For
Wildcat Capital Management, LLC	0	0	495,606	Abstain
DAFNA Capital Management LLC	469,000	0	0	For
State Street	289,238	49	0	For
Laurion Capital Management LP	250,600	0	0	For
Goldman Sachs	192,529	0	0	For
ARK ETF Trust	151,781	0	0	For
Wellington	136,215	0	0	For
Northern Trust	114,794	0	0	For
Point72	103,504	0	0	For
OAK RIDGE INVESTMENTS LLC	100,017	0	0	For
RICE HALL JAMES & ASSOCIATES, LLC	0	63,246	0	Against
MELLON INVESTMENTS Corp	44,749	0	0	For
BANK OF AMERICA NA	42,361	0	0	For
Equitable	36,088	0	0	For
Vanguard	35,099	0	0	For
Coastal Bridge Advisors, LLC	33,417	0	0	For
AMERIPRISE FINANCIAL INC	29,055	0	0	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

2. To approve the Company's 2024 non-employee director and officer compensation policy.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 22,359,904AGAINST: 3,433,075

UROGEN PHARMA LTD.’s own tally for this item (“Proposal 2 - 2024 Compensation Policy. The shareholders approved the 2024 Compensation Policy.”): 22,359,904 for, 3,433,075 against, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 54.3% for, 8% against (63% of the company cast a for/against vote).

The 40 asset managers below cast 97% of the shares they voted on this item FOR (1,511,299 for, 47,140 against).

FOR 74%ABSTAIN 24%

FOR: 1,511,299 (73.6%)AGAINST: 47,140 (2.3%)ABSTAIN: 495,606 (24.1%)

Largest asset managers voting on “To approve the Company's 2024 non-employee director and officer compensation policy.” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Against	Abstain	Vote
BlackRock	689,818	0	0	For
Wildcat Capital Management, LLC	0	0	495,606	Abstain
DAFNA Capital Management LLC	469,000	0	0	For
ARK ETF Trust	151,781	0	0	For
Equitable	36,088	0	0	For
Vanguard	31,480	0	0	For
Northern Trust	26,724	0	0	For
Lincoln Financial	16,400	0	0	For
Goldman Sachs	16,154	0	0	For
State Street	15,289	0	0	For
Global X	0	13,653	0	Against
CLEARWATER INVESTMENT TRUST	0	12,390	0	Against
John Hancock	10,660	0	0	For
New York Life	0	9,616	0	Against
Pacific Life	9,304	0	0	For
SEI	0	6,702	0	Against
Bridge Builder Trust	6,674	0	0	For
Fidelity	5,288	0	0	For
DWS	4,140	0	0	For
AIG/SunAmerica	3,200	0	0	For
Charles Schwab	0	3,180	0	Against
Voya	2,963	0	0	For
ALPS ETF Trust	2,818	0	0	For
Calvert	2,816	0	0	For
ProShares	1,672	0	0	For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

3. To approve an amendment to the Company's 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 800,000 shares.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 22,707,108AGAINST: 3,050,813

UROGEN PHARMA LTD.’s own tally for this item (“Proposal 3 - 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.”): 22,707,108 for, 3,050,813 against, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 55% for, 7% against (63% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (715,096 for, 0 against).

FOR 59%ABSTAIN 41%

FOR: 715,096 (59.1%)ABSTAIN: 495,606 (40.9%)

Largest asset managers voting on “To approve an amendment to the Company's 2017 Equity Incentive Plan to increase the number of ordinary shares ” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
Wildcat Capital Management, LLC	0	495,606	Abstain
BlackRock	313,975	0	For
ARK ETF Trust	151,781	0	For
Equitable	36,088	0	For
Vanguard	31,480	0	For
Northern Trust	26,724	0	For
Lincoln Financial	16,400	0	For
Goldman Sachs	16,154	0	For
State Street	15,289	0	For
Global X	13,653	0	For
CLEARWATER INVESTMENT TRUST	12,390	0	For
John Hancock	10,660	0	For
New York Life	9,616	0	For
Pacific Life	9,304	0	For
SEI	6,702	0	For
Bridge Builder Trust	6,674	0	For
Fidelity	5,288	0	For
DWS	4,140	0	For
AIG/SunAmerica	3,200	0	For
Charles Schwab	3,180	0	For
UNITED CAPITAL FINANCIAL ADVISORS, LLC	3,000	0	For
Voya	2,963	0	For
ALPS ETF Trust	2,818	0	For
Calvert	2,816	0	For
ProShares	1,672	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 24,210,538WITHHELD: 2,096,113

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D., FACS”): 24,210,538 for, 2,096,113 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 59% for, 5% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (290,568 for, 0 against).

FOR 41%ABSTAIN 59%

FOR: 290,568 (40.8%)ABSTAIN: 421,528 (59.2%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	0	313,975	Abstain
ARK ETF Trust	151,781	0	For
Equitable	26,860	9,228	For
Vanguard	31,480	0	For
Northern Trust	26,724	0	For
Lincoln Financial	0	16,400	Abstain
Goldman Sachs	16,154	0	For
State Street	0	15,289	Abstain
Global X	0	13,653	Abstain
CLEARWATER INVESTMENT TRUST	0	12,390	Abstain
John Hancock	10,660	0	For
New York Life	0	9,616	Abstain
Pacific Life	0	9,304	Abstain
SEI	0	6,702	Abstain
Bridge Builder Trust	0	6,674	Abstain
Fidelity	5,288	0	For
DWS	4,140	0	For
AIG/SunAmerica	3,200	0	For
Charles Schwab	0	3,180	Abstain
Voya	2,963	0	For
ALPS ETF Trust	2,818	0	For
Calvert	2,816	0	For
ProShares	1,672	0	For
Principal Exchange-Traded Funds	1,474	0	For
Morgan Stanley	0	1,060	Abstain

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 25,614,657WITHHELD: 691,994

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Cynthia M. Butitta”): 25,614,657 for, 691,994 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 62% for, 2% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (702,381 for, 0 against).

FOR 99%

FOR: 702,381 (98.6%)ABSTAIN: 9,715 (1.4%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	313,975	0	For
ARK ETF Trust	151,781	0	For
Equitable	36,088	0	For
Vanguard	31,480	0	For
Northern Trust	26,724	0	For
Lincoln Financial	16,400	0	For
Goldman Sachs	16,154	0	For
State Street	15,289	0	For
Global X	13,653	0	For
CLEARWATER INVESTMENT TRUST	12,390	0	For
John Hancock	10,660	0	For
New York Life	0	9,616	Abstain
Pacific Life	9,304	0	For
SEI	6,702	0	For
Bridge Builder Trust	6,674	0	For
Fidelity	5,288	0	For
DWS	4,140	0	For
AIG/SunAmerica	3,200	0	For
Charles Schwab	3,180	0	For
Voya	2,963	0	For
ALPS ETF Trust	2,818	0	For
Calvert	2,816	0	For
ProShares	1,672	0	For
Principal Exchange-Traded Funds	1,474	0	For
Morgan Stanley	1,060	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 26,274,644WITHHELD: 32,007

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Daniel G. Wildman”): 26,274,644 for, 32,007 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 64% for, 0.1% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (712,096 for, 0 against).

FOR 100%

FOR: 712,096 (100.0%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Vote
BlackRock	313,975	For
ARK ETF Trust	151,781	For
Equitable	36,088	For
Vanguard	31,480	For
Northern Trust	26,724	For
Lincoln Financial	16,400	For
Goldman Sachs	16,154	For
State Street	15,289	For
Global X	13,653	For
CLEARWATER INVESTMENT TRUST	12,390	For
John Hancock	10,660	For
New York Life	9,616	For
Pacific Life	9,304	For
SEI	6,702	For
Bridge Builder Trust	6,674	For
Fidelity	5,288	For
DWS	4,140	For
AIG/SunAmerica	3,200	For
Charles Schwab	3,180	For
Voya	2,963	For
ALPS ETF Trust	2,818	For
Calvert	2,816	For
ProShares	1,672	For
Principal Exchange-Traded Funds	1,474	For
Morgan Stanley	1,060	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

7. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 26,265,811WITHHELD: 40,840

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 26,265,811 for, 40,840 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 64% for, 0.1% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (711,096 for, 0 against).

FOR 99.8%

FOR: 711,096 (99.9%)ABSTAIN: 1,000 (0.1%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Vote
BlackRock	313,975	For
ARK ETF Trust	151,781	For
Equitable	36,088	For
Vanguard	31,480	For
Northern Trust	26,724	For
Lincoln Financial	16,400	For
Goldman Sachs	16,154	For
State Street	15,289	For
Global X	13,653	For
CLEARWATER INVESTMENT TRUST	12,390	For
John Hancock	10,660	For
New York Life	9,616	For
Pacific Life	9,304	For
SEI	6,702	For
Bridge Builder Trust	6,674	For
Fidelity	5,288	For
DWS	4,140	For
AIG/SunAmerica	3,200	For
Charles Schwab	3,180	For
Voya	2,963	For
ALPS ETF Trust	2,818	For
Calvert	2,816	For
ProShares	1,672	For
Principal Exchange-Traded Funds	1,474	For
Morgan Stanley	1,060	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

8. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Fred E. Cohen

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 25,753,702WITHHELD: 552,949

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Fred E. Cohen, M.D., D.Phil.”): 25,753,702 for, 552,949 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 63% for, 1% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (614,875 for, 0 against).

FOR 86%14%

FOR: 614,875 (86.3%)ABSTAIN: 97,221 (13.7%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	313,975	0	For
ARK ETF Trust	151,781	0	For
Equitable	9,228	26,860	Abstain
Vanguard	31,480	0	For
Northern Trust	0	26,724	Abstain
Lincoln Financial	0	16,400	Abstain
Goldman Sachs	16,154	0	For
State Street	0	15,289	Abstain
Global X	13,653	0	For
CLEARWATER INVESTMENT TRUST	12,390	0	For
John Hancock	10,660	0	For
New York Life	9,616	0	For
Pacific Life	9,304	0	For
SEI	6,702	0	For
Bridge Builder Trust	6,674	0	For
Fidelity	5,288	0	For
DWS	0	4,140	Abstain
AIG/SunAmerica	3,200	0	For
Charles Schwab	3,180	0	For
Voya	0	2,963	Abstain
ALPS ETF Trust	2,818	0	For
Calvert	0	2,816	Abstain
ProShares	1,672	0	For
Principal Exchange-Traded Funds	1,474	0	For
Morgan Stanley	1,060	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

9. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 26,184,412WITHHELD: 122,239

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: James A. Robinson, Jr.”): 26,184,412 for, 122,239 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 64% for, 0.3% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (696,890 for, 0 against).

FOR 98%

FOR: 696,890 (97.9%)ABSTAIN: 15,206 (2.1%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	313,975	0	For
ARK ETF Trust	151,781	0	For
Equitable	36,088	0	For
Vanguard	31,480	0	For
Northern Trust	26,724	0	For
Lincoln Financial	16,400	0	For
Goldman Sachs	16,154	0	For
State Street	15,289	0	For
Global X	13,653	0	For
CLEARWATER INVESTMENT TRUST	0	12,390	Abstain
John Hancock	10,660	0	For
New York Life	9,616	0	For
Pacific Life	9,304	0	For
SEI	6,702	0	For
Bridge Builder Trust	6,674	0	For
Fidelity	5,288	0	For
DWS	4,140	0	For
AIG/SunAmerica	3,200	0	For
Charles Schwab	3,180	0	For
Voya	2,963	0	For
ALPS ETF Trust	2,818	0	For
Calvert	0	2,816	Abstain
ProShares	1,672	0	For
Principal Exchange-Traded Funds	1,474	0	For
Morgan Stanley	1,060	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

10. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 26,092,046WITHHELD: 214,605

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Leana S. Wen, M.D., M.Sc.”): 26,092,046 for, 214,605 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 63% for, 0.6% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (676,535 for, 0 against).

FOR 95%

FOR: 676,535 (95.0%)ABSTAIN: 35,561 (5.0%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	313,975	0	For
ARK ETF Trust	151,781	0	For
Equitable	36,088	0	For
Vanguard	31,480	0	For
Northern Trust	26,724	0	For
Lincoln Financial	16,400	0	For
Goldman Sachs	16,154	0	For
State Street	15,289	0	For
Global X	0	13,653	Abstain
CLEARWATER INVESTMENT TRUST	0	12,390	Abstain
John Hancock	10,660	0	For
New York Life	9,616	0	For
Pacific Life	9,304	0	For
SEI	0	6,702	Abstain
Bridge Builder Trust	6,674	0	For
Fidelity	5,288	0	For
DWS	4,140	0	For
AIG/SunAmerica	3,200	0	For
Charles Schwab	3,180	0	For
Voya	2,963	0	For
ALPS ETF Trust	2,818	0	For
Calvert	0	2,816	Abstain
ProShares	1,672	0	For
Principal Exchange-Traded Funds	1,474	0	For
Morgan Stanley	1,060	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

11. To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 25,594,793WITHHELD: 711,858

UROGEN PHARMA LTD.’s own tally for this item (“Elect Director: Stuart Holden, M.D.”): 25,594,793 for, 711,858 withheld, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 62% for, 2% withheld (64% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (712,096 for, 0 against).

FOR 100%

FOR: 712,096 (100.0%)

Largest asset managers voting on “To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold of” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Vote
BlackRock	313,975	For
ARK ETF Trust	151,781	For
Equitable	36,088	For
Vanguard	31,480	For
Northern Trust	26,724	For
Lincoln Financial	16,400	For
Goldman Sachs	16,154	For
State Street	15,289	For
Global X	13,653	For
CLEARWATER INVESTMENT TRUST	12,390	For
John Hancock	10,660	For
New York Life	9,616	For
Pacific Life	9,304	For
SEI	6,702	For
Bridge Builder Trust	6,674	For
Fidelity	5,288	For
DWS	4,140	For
AIG/SunAmerica	3,200	For
Charles Schwab	3,180	For
Voya	2,963	For
ALPS ETF Trust	2,818	For
Calvert	2,816	For
ProShares	1,672	For
Principal Exchange-Traded Funds	1,474	For
Morgan Stanley	1,060	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

12. To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2025 annual meeting of shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 33,039,893AGAINST: 8,345

UROGEN PHARMA LTD.’s own tally for this item (“Proposal 5 - Engagement of PricewaterhouseCoopers LLP as independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's 2025 annual me”): 33,039,893 for, 8,345 against, per its Form 8-K filed 2024-08-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,169,954 outstanding shares: 80% for, 0.1% against (80% of the company cast a for/against vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (712,096 for, 0 against).

FOR 100%

FOR: 712,096 (100.0%)

Largest asset managers voting on “To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at UROGEN PHARMA LTD., 2024-2025
Asset manager	For	Vote
BlackRock	313,975	For
ARK ETF Trust	151,781	For
Equitable	36,088	For
Vanguard	31,480	For
Northern Trust	26,724	For
Lincoln Financial	16,400	For
Goldman Sachs	16,154	For
State Street	15,289	For
Global X	13,653	For
CLEARWATER INVESTMENT TRUST	12,390	For
John Hancock	10,660	For
New York Life	9,616	For
Pacific Life	9,304	For
SEI	6,702	For
Bridge Builder Trust	6,674	For
Fidelity	5,288	For
DWS	4,140	For
AIG/SunAmerica	3,200	For
Charles Schwab	3,180	For
Voya	2,963	For
ALPS ETF Trust	2,818	For
Calvert	2,816	For
ProShares	1,672	For
Principal Exchange-Traded Funds	1,474	For
Morgan Stanley	1,060	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Largest UROGEN PHARMA LTD. shareholders voting in 2024-2025

Ranked by the number of UROGEN PHARMA LTD. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 41,169,954 shares outstanding at the time of that meeting.

Top UROGEN PHARMA LTD. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	ADAGE CAPITAL PARTNERS GP, L.L.C.	11.05%
2	RTW INVESTMENTS, LP	8.64%
3	RA CAPITAL MANAGEMENT, L.P.	7.49%
4	MENORA MIVTACHIM HOLDINGS LTD.	5.56%
5	GREAT POINT PARTNERS LLC	4.97%
6	Cormorant Asset Management, LP	3.57%
7	BlackRock	2.03%
8	SILVERARC CAPITAL MANAGEMENT, LLC	1.98%
9	Wildcat Capital Management, LLC	1.20%
10	DAFNA Capital Management LLC	1.14%

Reported UROGEN PHARMA LTD. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

UROGEN PHARMA LTD. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
The Toronto-Dominion Bank	6.36%	13G
BlackRock	5.89%	13F
Menora Mivtachim Holdings Ltd	5.59%	13G
Soleus Capital Master Fund, L.P.	5.31%	13G
Morgan Stanley	2.08%	13F
State Street	1.93%	13F
Geode Capital	1.15%	13F
Millennium Management	1.03%	13F
JPMorgan Chase	0.90%	13F
T. Rowe Price	0.90%	13F

Percentages above are of 41,169,954 shares outstanding, as reported by UROGEN PHARMA LTD. on its Form 10-Q dated 2024-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from UROGEN PHARMA LTD.’s 10-Q dated 2024-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At UROGEN PHARMA LTD.'s shareholder meeting held 2024-08-06, in the 2024-2025 proxy season, 132 asset managers reported how they voted on 12 ballot items in their SEC Form N-PX filings, covering 1,207 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: UROGEN PHARMA LTD.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-08-08.

UROGEN PHARMA LTD. proxy season coverage: 2024-2025 (this page) · 2025-2026.